A Phase 3 clinical trial NCT02482753 assessed the safety and efficacy of Tucidnostat (Chidamide) in combination with aromatase inhibitor Exemestane in patients with advanced Estrogen Receptor + (ER+) BC. This evidence concerns the gene ESR1 and breast cancer.